First edition · v1.0 · regulatory verification 04/10/2026
A sterility test without growth does not demonstrate sterility, growth promotion is not method suitability, endotoxins are not pyrogens: the microbiology laboratory governed with the source next to every value.
A quality and technical guide for those who organise, perform, verify and govern the GMP QC microbiology laboratory, from sample to decision: organisation and personnel, sterility testing and isolators, bioburden and endotoxins, rapid methods and identification, media, strains and incubation, samples and samplers, equipment, microbiological OOS results and contract laboratories. 18 chapters in six parts and 6 appendices, 246 pages in the Italian edition and 248 in the English one, and 16 editable tools in Word and Excel, for €179.
246 pages (ITA) · 248 (ENG) · PDF A418 chapters in six parts + 6 appendices16 tools: 8 Word + 8 Excel99 sources in the register91 tracked decisionsDigital product: download after payment
One language per purchase, chosen by the variant. The ITA - Italiano variant gives you the PDF guide and the 16 tools in Italian; the ENG - English variant gives them in English. Both editions have the same structure, the same tools and the same codes MB-TK-01…16. There are no files in French, German or Spanish.
The decisions it helps you make
Every chapter starts from a laboratory decision and closes it with who decides, on what basis and where it is recorded: 91 decision codes, each linked to the tool where it is documented.
Programme, reference texts and boundaries
Programme owner, reference texts per product and market, areas, flows and segregation, where the sterility test is performed and on which device cultures are handled.
Chapters 1–2 · MB-TK-01
Personnel and aseptic technique
Which evidence authorises an analyst to perform a test, with observed assessment and a simulated test with medium, and when the authorisation must be renewed.
Chapter 3 · MB-TK-02
Sterility test method and suitability
Membrane filtration or direct inoculation, sampling plan and suitability per product, knowing that the test does not demonstrate sterility.
Chapter 4 · MB-TK-03
Isolator and bio-decontamination cycle
Incoming BI population, log reduction by position, peroxide residue and media stasis, temperature-corrected leak test, glove tests.
Chapter 5 · MB-TK-04
Positive test: invalidation or batch rejection
With which evidence a positive can be attributed unequivocally to a laboratory error, who approves an invalidation and when the investigation moves to manufacturing and other batches.
Chapter 6 · MB-TK-05
Bioburden and enumeration
Method, quantity tested and neutralisation with recoveries and exact intervals, a declared counting convention, low or zero results and objectionable organisms.
Chapter 7 · MB-TK-06
Endotoxins
Technique and reagent, MVD and routine dilution with the positive product control, a hold study on masking, the pyrogenicity strategy and the move to recombinant reagents.
Chapter 8 · MB-TK-07
Rapid methods, identification and colony counters
Criteria set before testing: colony counter agreement with the manual count, qualification of the identification system and its library, non-inferiority and equivalence of the rapid method.
Chapter 9 · MB-TK-08
Media, growth promotion and strains
A designated group including local isolates, a release rule after the outcome for every organism, change control of recipes, passages and traceability of cultures.
Chapters 10–11 · MB-TK-09, MB-TK-10
Incubation and excursions
Conditions and load that make the result sensitive, the logger's logging interval and an impact assessment of every episode outside the range.
Chapter 12 · MB-TK-11
Samples, samplers and EM data
Acceptance and chain of custody, maximum time from sampling to testing, the real flow rate of air samplers, surface recovery, reading and transfer of EM results.
Chapters 13–15 · MB-TK-12, MB-TK-13
Equipment, OOS results and contract laboratories
Qualification of autoclaves, cabinets and incubators; phases I and II of a microbiological OOS with CAPA and effectiveness; suitability of a contract laboratory and periodic review.
Chapters 16–18 · MB-TK-14, MB-TK-15, MB-TK-16
The myths it takes apart
Statements that circulate as "requirements" and that the sources write differently. For each one the guide gives the document, clause, nature and jurisdiction.
"A sterility test without growth proves the batch is sterile." The test has statistical limitations that the sources state (EU GMP Annex 1, 10.5; Annex 17, 4.2). The example in the 2004 FDA guidance (XI.B): 20 units from a batch with 0.1% contaminated units have a 98% probability of passing the test; 0 positives out of 20 are compatible, at 95%, with rates up to 13.91% [DEMONSTRATION EXAMPLE] (Chapters 4 and 6).
"Same species in the test and in the laboratory environment: the positive is invalidated." Under the 2004 FDA guidance (XI.C) a test is invalidated only for an unequivocal, documented laboratory error; when the evidence is inconclusive the batch is rejected and the investigation extends to manufacturing. The species demonstrates neither the strain nor the route; growth in one medium only is still a positive; the invalidation is approved by laboratory QA (Chapter 6, Case A).
"Repeating the sterility test once is always allowed." A repeat after definitive attribution to an error is a regulatory requirement in the USA for licensed biologics (21 CFR 610.12(f)); for drugs the 2004 FDA guidance (XI.C) and 21 CFR 211.192 apply. The guide gives source and nature and does not present it as a rule where it is not one (Chapter 6).
"If the medium passes growth promotion, the method is suitable." Method suitability, validation and verification are distinct levels (EU GMP Chapter 6, 6.15; Annex 15, 9.2) and the growth promotion test (GPT) of a media batch is none of the three (Annex 1, 10.9). A medium that grows the reference strains can fail on a local isolate (Chapters 4 and 10, Case D).
"The endotoxin test covers pyrogenicity, and the rabbit test remains a Ph. Eur. option." LAL and recombinant reagents detect only Gram-negative endotoxins: using them as the only pyrogenicity control requires a risk assessment. Ph. Eur. 5.1.13 'Pyrogenicity' has been in force since 01/07/2025 and chapter 2.6.8 'Pyrogens' has been suppressed since 01/01/2026 (Chapter 8).
"The regulations set incubation times and temperatures." No regulation sets a single value. Annex 1, 9.4, asks for EM programme conditions set by risk assessment, with no value; the 30–35 °C and 20–25 °C in the 2004 FDA guidance for EM are indications, not requirements, and site-specific studies diverge (Chapter 12).
"Media recovery is sampling efficiency, and ISO 14698 is the reference standard." Annex 1, 9.29, asks for supporting data on the recovery efficiency of the sampling methods: the GPT of the plates shows that the medium supports growth, not how much the plate or swab removes from the surface. ISO 14698-1 and -2 were withdrawn on 16/03/2026 with no replacement indicated (Chapter 14).
"A laminar flow clean bench is a biological safety cabinet, and bio-decontamination sterilises the isolator." Under the WHO Laboratory Biosafety Manual (4th edition, 2020) clean benches are not primary containment; under PIC/S PI 014-3, 5.3, a sporicidal process applied to an isolator is not considered a sterilisation process (Chapters 5 and 16).
"An ISO/IEC 17025-accredited contract laboratory is qualified." Accreditation demonstrates competence within the accredited scope; EU GMP Chapter 7, 7.5, requires the contract giver to assess the "legality, suitability and the competence" of the laboratory for its own product. In Case E an external "not detected" retest hides a generic suitability test without a neutraliser (Chapter 18).
The guide
18 chapters in six parts, named after the six themes of the Microbiology Laboratory and Sterility Testing hub, and 6 appendices. Chapters 2–18 follow seventeen fixed sections, always in the same order: requirement → interpretation → risk → decision → action → evidence → audit readiness. Four status labels and seven nature labels tell you what each source is worth and in which jurisdiction.
The toolkit
16 editable tools: 8 Word templates and 8 Excel workbooks, each as a clean template and as a filled-in example. The Excel workbooks have a Read_Me with the functional specification and the Formulas, Error_Check and Assumptions_Limits sheets, a "Reason" column next to every outcome, and return only "Comparison with the entered criteria" or "Assessment required".
Five integrated cases
In the microbiology laboratory of the fictitious company Torvenza Pharma: a positive sterility test with the same species, a different strain and the batch rejected (Case A), cycle development for a testing isolator with a cold spot and a peroxide residue (B), the routine endotoxin dilution and masking over time, rFC included (C), growth promotion failing on a local isolate after the media batch was released (D), a count OOS on a non-sterile product with an external retest and a contract laboratory (E). The "Questions" sheet of MB-TK-16 holds 120 inspector questions.
Regulatory status verified as of 04/10/2026
The guide describes the regulatory and technical framework as of 04/10/2026; documents published or amended after this date are not considered. Every source carries a status label (current, draft, in development, superseded) and a nature label, with the jurisdiction where it applies; texts published but not yet applicable carry no status label. The points that most often change the reading:
- EU GMP Annex 1 (2022) has been operational since 25/08/2023 and fully applicable, point 8.123 included, since 25/08/2024. The revised Annex 19 applies from 24/09/2026; PIC/S PE 009-18 is in force from the same date.
- Pyrogens in the Ph. Eur.: chapter 5.1.13 'Pyrogenicity' has been in force since 01/07/2025; chapter 2.6.8 'Pyrogens' has been suppressed since 01/01/2026. These are two distinct dates.
- Endotoxins with recombinant reagents: Ph. Eur. 2.6.32 is current until 31/12/2026; method G of 2.6.14 applies from 01/01/2027 (Issue 13.1, published, not yet applicable). USP 〈86〉 (May 2025) is official but not 'applicable'. The FDA Q&A 'Pyrogen and Endotoxins Testing' Edition 2 (March 2026, page current as of 18/03/2026) is current; Edition 1 of June 2012 is superseded.
- Pharmacopoeias: Ph. Eur. 12th Edition up to Issue 12.3 and USP–NF 2026, Issue 5 (official from 01/10/2026) are applicable. Ph. Eur. 5.1.9 has been revised since 01/01/2026; the revision of 5.1.6 on alternative methods applies from 01/04/2027, and until then the previous text remains in force.
- PIC/S PI 012-3 and PI 014-3 (25/09/2007), on sterility testing and isolators, are guidance for inspectors, dated and not mandatory for industry: their values are reported only as historical guidance. The guideline for the microbiology laboratory is WHO TRS 961, Annex 2; TRS 1052, Annex 4 excludes it.
- Technical standards: ISO 14698-1 and -2 have been withdrawn since 16/03/2026 with no replacement indicated; for biological safety cabinets the EN 12469:2025 series (parts 1, 2 and 5) and NSF/ANSI 49-2026 apply, both voluntary standards.
- Drafts: the 2025 revisions of Annex 11, Chapter 4 and Chapter 1 are drafts whose consultation has closed; the revision of Annex 15 is in development, with a draft planned for December 2026; the Pharmacopeial Forum proposals for USP 〈1117〉, 〈1113〉 and 〈1085〉 are not current text.
Updates included. Appendix F lists the events that trigger re-verification of the guide: Ph. Eur. Issues 13.1, 13.2 and 13.3, new USP–NF Issues, Pharmacopeial Forum proposals, final texts of the Annex 11, Chapter 4 and Chapter 1 revisions, the draft of the revised Annex 15, ISO and EN standards in development, the effects of the new EU pharmaceutical legislation, the status of Annex 1 in Great Britain and NSF/ANSI 49-2026. When the texts change, you receive the revised guide and toolkit at no extra cost. The guide does not announce release dates for its own revisions: the revision on sale is shown on this page.
The 16 tools, in six groups
One folder per part of the book, with the exact titles of the English edition. No operational value is preloaded: incubation times and temperatures, numbers of units and volumes to be tested, inocula, recovery and suitability criteria, growth promotion test criteria, numbers of passages, countable ranges, bioburden and endotoxin limits, routine dilutions, log reduction targets, peroxide residues and aeration times, maximum sample hold times, requalification and review frequencies, numbers of replicates and acceptance criteria remain <to be defined>, with the decision code.
01_Lab_Organisation · Laboratory Organisation
EXCELMB-TK-01 · Laboratory Test, Workflow and Responsibility Matrix
Areas, tests with reference text and owner, flows, R/A/C/I roles, equipment, interfaces and boundaries with the sister guides; flags tests with no owner. It neither qualifies nor decides.
WORDMB-TK-02 · Personnel and Aseptic Technique Qualification Programme
Initial qualification, maintenance and requalification of analysts by activity: training, observed assessment, simulated test with medium, unfavourable outcomes.
02_Sterility_Isolators · Sterility Testing and Isolators
WORDMB-TK-03 · Sterility Test Method Suitability Protocol
Protocol and report per product: method, sampling plan, parameters, strains, environment, controls and the statistical limitations of the test; the growth criterion is that of the applied chapter.
EXCELMB-TK-04 · Isolator Bio-decontamination Cycle Log and Analysis
Incoming BIs, log reduction by position, D values, stasis against the chamber sensor, temperature-corrected leak test, glove tests.
WORDMB-TK-05 · Positive Sterility Test Investigation Form
From reading to decision: session controls, identification and typing, laboratory and manufacturing hypotheses, extension to other batches; no automatic invalidation criterion.
03_Methods_Technologies · Microbiological Methods and Technologies
EXCELMB-TK-06 · Enumeration, Recovery and Method Suitability Calculator (Poisson, MPN)
Concentrations with the declared convention, exact Poisson intervals, index of dispersion, MPN, recoveries and neutralisation with CIs, survival study.
EXCELMB-TK-07 · Endotoxin Calculator (MVD, Dilutions, Positive Product Control, Interference)
MVD and dilutions, composite samples, PPC recovery and margin by dilution, percentage of the limit, hold studies and retrospective assessment; it does not choose the routine dilution.
WORDMB-TK-08 · Rapid Method, Identification System and Colony Counter Evaluation Protocol
Three evaluations with criteria set in advance: colony counter agreement, qualification of the identification system and its library, non-inferiority and equivalence of the rapid method.
04_Media_Strains_Incubation · Media, Strains and Incubation
EXCELMB-TK-09 · Culture Media Batch and Growth Promotion Register
Batches, preparation, designated group, GPT by organism with ratio and exact CI, release rule; flags a batch released before the outcome for every organism.
WORDMB-TK-10 · Reference Strain Management Model Procedure
Procurement, seed lots, working cultures with passage count, purity and identity, local isolates, storage deviations.
EXCELMB-TK-11 · Incubation Excursion Calculator
From the logger series: episodes outside the range, duration, extreme value, area outside the limit, effect of the logging interval, impact assessment by episode.
05_Sampling_Samples · Sampling and Sample Management
WORDMB-TK-12 · Sample Receipt, Chain of Custody and Hold Time Checklist
Acceptance, chain of custody, time from sampling to testing against the decided maximum, storage while awaiting testing, shipments to a contract laboratory.
EXCELMB-TK-13 · Air Sampler and Surface Recovery Calculator
Flow rate verification, effect of flow rate error, positive-hole correction, Stokes d₅₀, surface recovery with exact CI; EM sites and limits stay with the programme.
06_Equipment_Reliability · Equipment and Result Reliability
WORDMB-TK-14 · Laboratory Autoclave, Biosafety Cabinet and Incubator Qualification Protocol
IQ, OQ, PQ and requalification for defined loads, cabinets and clean benches, incubators; routine checks, out of service and return to service.
WORDMB-TK-15 · Microbiological OOS Investigation and CAPA Form
Phase I, consistency of the counts, objectionables, discriminating tests, retests and resampling, extension to manufacturing, contract laboratory, CAPA and effectiveness.
EXCELMB-TK-16 · Contract Laboratory Assessment and Periodic Review
Contract, audits, completeness of external results; indicators, negative control trending, checklist, inspector questions and source review. Accreditation alone does not qualify a laboratory.
In the ITA - Italiano variant the same 16 tools carry the titles of the Italian edition and the same codes MB-TK-01…16. Every tool also exists as a filled-in example on the Torvenza Pharma case, in the 07_Examples folder.
Ready to use tomorrow morning
| The situation | What you use |
|---|
| A new product to bring into sterility testing | Chapter 4 + MB-TK-03: choice between membrane filtration and direct inoculation, sampling plan, suitability per product with the criterion of the applied chapter and stated statistical limitations. |
| A turbid canister and a proposal to invalidate the test | Chapter 6 + MB-TK-05: session controls, identification and typing, hypothesis matrix, laboratory QA decision and extension to other batches. It is Case A. |
| A new testing isolator or a bio-decontamination cycle to develop | Chapter 5 + MB-TK-04: incoming BIs, log reduction by position, aeration justified by the stasis test, temperature-corrected leak test. It is Case B. |
| A formulation with chelating agents and surfactants, or the move from LAL to rFC | Chapters 8 and 13 + MB-TK-07 and MB-TK-12: interference screening, routine dilution, hold study, maximum sample hold time, retrospective assessment of released batches. It is Case C. |
| A released media batch that fails GPT on a local isolate | Chapters 10 and 11 + MB-TK-09 and MB-TK-10: designated group, release rule, cause test, change control of the recipe, impact on the readings of the batch. It is Case D. |
| An out-of-specification count on a non-sterile product and an external "not detected" retest | Chapters 7, 13, 17 and 18 + MB-TK-06, MB-TK-12, MB-TK-15 and MB-TK-16: phase I, decay during the hold, objectionables, review of the contract laboratory's raw data. It is Case E. |
| A temperature excursion in an incubator | Chapters 12 and 16 + MB-TK-11 and MB-TK-14: episodes from the logger series, effect of the logging interval, impact assessment by episode, out of service and return to service. |
| A GMP inspection with the microbiology laboratory in scope | Chapters 1, 2 and 18 + MB-TK-01 and MB-TK-16: tests with owners, flows and boundaries, periodic review, 120 inspector questions and 186 checklist rows built for training. |
What the guide does not do
It gives no universal numbers. No universal values for incubation times and temperatures, recoveries, GPT criteria, dilutions, numbers of units, replicates, passages or frequencies. Where a source states a value, the guide reports it with document, clause, nature and context; numerical examples are marked [DEMONSTRATION EXAMPLE].
It never declares a method suitable or a result valid. No tool in the toolkit returns a favourable outcome: the only outcomes are "Comparison with the entered criteria" or "Assessment required", and missing data always lead to the latter. The decision on a result, a media batch, an item of equipment or an investigation rests with the quality function, on the basis of data and a documented assessment.
It does not duplicate the sister guides. Sites, frequencies, limits and trends of the environmental monitoring programme are in the "Operational Guide to Environmental Monitoring Systems in GMP Facilities"; Annex 1 as a whole in "EU GMP Annex 1 (2022): The Complete Map — GuideGxP Operational Guide"; design and criteria of the aseptic process simulation in "Aseptic Process Simulation (Media Fill): Designing, Running and Defending the APS under Annex 1 and FDA"; general instrument qualification in the "Operational Guide to Analytical Instrumentation in the GMP QC Laboratory (First Edition + Toolkit)"; data governance and audit trail review in "Data Integrity in GMP – Operational Guide to Governance, Audit Trail Review and QC Laboratories". This guide covers the laboratory side and how it connects to those requirements.
It is not legal advice and does not reproduce subscription texts. It describes the texts, status and force of the sources. USP–NF, Ph. Eur., JP, ISO, EN, NSF/ANSI and PDA are cited by title, number, edition and status, with no content, tables or numerical criteria; Ph. Eur. texts are reported from official EDQM sources, without direct consultation.
Contents: six parts, 18 chapters
Chapter titles of the English edition. Every chapter closes with a checklist, related tools and articles, decisions and the chapter's sources.
Part I — Laboratory Organisation
- 1. Regulatory basis, responsibilities and governance of the microbiology laboratory
- 2. Organisation, workflows, premises and segregation
- 3. Personnel: qualification, aseptic technique and competence
Part II — Sterility Testing and Isolators
- 4. Sterility test method: membrane filtration, direct inoculation, method suitability
- 5. Isolators for sterility testing and bio-decontamination
- 6. Execution, aseptic controls and investigation of the positive test
Part III — Microbiological Methods and Technologies
- 7. Bioburden and enumeration: recovery and suitability
- 8. Endotoxins: methods, recombinant reagents, interference
- 9. Rapid methods, microbial identification and colony counters
Part IV — Media, Strains and Incubation
- 10. Culture media: preparation, sterilisation, storage and growth promotion
- 11. Reference strains: traceability and management
- 12. Incubation: conditions, times and excursions
Part V — Sampling and Sample Management
- 13. Samples: receipt, chain of custody and timing
- 14. Air samplers and surface recovery (laboratory side)
- 15. EM samples: incubation, reading, counting and data (interface with the EM programme)
Part VI — Equipment and Result Reliability
- 16. Laboratory autoclaves, biological safety cabinets and clean benches, incubators
- 17. Microbiological OOS results, investigation and CAPA
- 18. Contract laboratories, data integrity of microbiological data and periodic review
Appendices A–F. A ITA/ENG glossary · B Source matrix · C Chapter, toolkit and article matrix · D Toolkit instructions · E Register of assumptions and limitations · F Revision and change log.
What the package contains
After payment you download a ZIP file with the guide and the toolkit in the language of the chosen variant.
- The complete PDF guide. 246 A4 pages in the Italian edition, 248 in the English one; clickable table of contents and bookmarks.
- 16 editable tools. 8 Word templates and 8 Excel workbooks, in the folders 01_Lab_Organisation…06_Equipment_Reliability.
- 16 filled-in examples and demonstration datasets. The examples on the Torvenza Pharma case in the 07_Examples folder, with the datasets DS-01…DS-11 (laboratory, isolator cycles, counts and suitability, endotoxins, growth promotion, incubator logger, air sampler, test cases, colony counter, rapid method, contract laboratory) in .csv and .xlsx.
- Support files. README, toolkit index, field glossary and chapter–toolkit–article matrix in the 00_Read_Me folder.
- Verification. Test Log with one row per tool, test case and file, language parity report, check of example values and a manifest with the SHA-256 hash of every file, in the 08_Verification folder.
Read the excerpt before you buy
The free excerpt is made of real pages: 16 pages in the Italian edition, 16 in the English one. It contains the presentation with the regulatory and technical status box and the labels, the full table of contents, from Chapter 4 what the sterility test can demonstrate, membrane filtration and direct inoculation, suitability, validation and verification, from Chapter 6 the invalidation of a positive test and the complete Case A, real pages of three tools (MB-TK-07, MB-TK-04 and MB-TK-05) and the list of what the purchase includes.
Specifications
| Format | A4 PDF with clickable table of contents and bookmarks; tools in .docx and .xlsx |
| Pages and chapters | 246 pages (ITA edition) · 248 pages (ENG edition) · 18 chapters in six parts + 6 appendices (A–F) |
| Toolkit | 16 editable tools: 8 Word + 8 Excel, codes MB-TK-01…16, plus 16 filled-in examples |
| File languages | One language per purchase: ITA - Italiano or ENG - English. There are no files in French, German or Spanish. |
| Edition and revision | First edition, October 2026 · v1.0 · tools v1.0 |
| Regulatory verification | 04/10/2026 (status of every source as of that date) |
| References | EU (EudraLex, EMA) · PIC/S · WHO · ICH · USA (21 CFR, FDA guidance) · United Kingdom (essential status) · USP–NF and Ph. Eur. (texts not reproduced) · ISO, EN and NSF/ANSI standards · scientific literature |
| Sources and decisions | 99 sources in the Appendix B register · 91 decisions tracked in Appendix D |
| Free excerpt | 16 pages (ITA edition) · 16 pages (ENG edition) |
| Updates | When the texts change, you receive the revised guide and toolkit at no extra cost. |
| Delivery | Digital product: download of the ZIP file after payment. No shipping: the 3D image of the volume is a graphic rendering; there is no printed book. |
| Software requirements | A PDF reader; Microsoft Word; Excel 2016 or LibreOffice: the Excel workbooks were recalculated with LibreOffice in the Test Log runs. No macros, no external links; protected "Ref_…" reference sheets. |
| Licence | Individual use and internal use within the purchasing company: a personal, non-exclusive, non-transferable licence under the site's Legal Notice; printing for internal use only; sharing the files with third parties is prohibited. |
| Price | €179.00 per variant (guide + toolkit in the chosen language) |
Limits of use
- The Excel workbooks are calculation templates with specification, tests and limits, not validated software: before GMP use, the laboratory verifies them in its own quality system by repeating the relevant Test Log cases.
- Simulated case: Torvenza Pharma S.p.A. is a fictitious company; its microbiology laboratory, batches and data are hypothetical. Every Torvenza value is a demonstration internal criterion, not a recommended value or an acceptance criterion.
- No sheet declares a method suitable or a result valid: the only outcomes are "Comparison with the entered criteria" or "Assessment required". The guide does not replace the assessment of the quality function and does not decide what happens to a batch.
- The guide does not replace the official texts cited and is not personalised legal, regulatory or quality advice. The species of the compendial strains are not reported: for strains, criteria and methods the current text prevails.
- The inspector questions are built for training and do not reproduce real findings; the fifteen FDA Warning Letters cited are verified, anonymised and each illustrates one topic. No guarantee of audit or inspection outcomes, which depend on context and application.
- The numerical examples were recalculated independently by the editorial team; the guide and the toolkit have not undergone independent third-party validation.
Who it is for. Heads and analysts of the QC microbiology laboratory, laboratory QA, sterility assurance, CQV, leads for sterility testing and isolators, endotoxins, media and strains, laboratory IT/CSV, procurement and those who manage contract laboratories. It is written for those who organise, perform, verify or govern microbiological testing: sterility testing, bioburden and enumeration, endotoxins, rapid methods and identification, growth promotion, incubation, EM samples and laboratory equipment, and need to know which text every value comes from, with what force and in which jurisdiction.
Who it is not for. It is not a guide to the environmental monitoring programme, to Annex 1 as a whole, to aseptic process simulation, to general instrument qualification or to data governance (the subjects of the sister guides linked on this page). Out of scope: validation of production sterilisation processes, containment levels and national biosafety legislation, mycoplasma and viral tests and cell-based preparations and tissues, container closure integrity testing and biological waste disposal; the microbiological assay of antibiotics and the antimicrobial effectiveness test are cited only as an interface.
Frequently asked questions
Which language are the files in?
The language of the chosen variant: ITA - Italiano or ENG - English. Each purchase includes the guide and the toolkit in one language. There are no files in French, German or Spanish.
Is it a printed book?
No. It is a digital product: after payment you download a ZIP file with the PDF and the tools. No shipping; the 3D image is only a rendering of the volume.
Does the guide give incubation times, recovery or GPT criteria that apply to everyone?
No, because no regulation sets them. It reports the values the sources state, with their nature (the 50–200% recovery in WHO TRS 961, Annex 2, is guidance for media only; the 30–35 °C and 20–25 °C in the 2004 FDA guidance for EM are indications; five passages from the collection culture are a convention), and the method for deciding the laboratory's own, each with its decision code (Chapters 10, 11 and 12).
Do the tools say whether a method is suitable or a result is valid?
No. They return only "Comparison with the entered criteria" or "Assessment required"; missing data, exceedances or criteria not entered always lead to the latter, with the reason. The decision rests with the quality function.
Does it reproduce USP and Ph. Eur. criteria, tables and strains?
No. Compendial texts are sold by subscription: the guide reports their number, title, edition and status, describes the structure of the decision and does not give the species of the compendial strains. Ph. Eur. texts are reported from official EDQM sources, without direct consultation; for requirements, methods and criteria the current text prevails.
How does it handle rFC, method G and USP 〈86〉?
With the status of each text as of 04/10/2026: Ph. Eur. 2.6.32 current until 31/12/2026, method G of 2.6.14 from 01/01/2027 (published, not yet applicable), USP 〈86〉 official but not 'applicable', the March 2026 FDA Q&A Edition 2 current. Case C shows that the recombinant reagent alone does not solve masking (Chapter 8).
Does it cover the environmental monitoring programme?
Only as an interface. The guide covers the laboratory side: receipt, incubation, reading and counting of EM samples, air samplers and surface recovery. Sites, frequencies, limits and trends of the programme are in the Environmental Monitoring sister guide linked on this page.
Does it apply to the United States?
The main reference is the EU, with PIC/S and WHO as guidance; for the United States the guide covers 21 CFR 211 and, for licensed biologics, 610 and 600.3, the FDA aseptic processing guidance (October 2004), the pyrogen and endotoxins Q&A Edition 2, the OOS guidance (May 2022, chemical scope) and the CGMP Q&As; the 1993 inspection guide and the FDA laboratory manuals are not guidance.
Are the Excel workbooks validated?
They are not validated software. Each one has a Read_Me with the functional specification, readable formulas, error checks and a Test Log of the tests run: the laboratory verifies them in its own system before GMP use.
What happens when the reference texts change?
Appendix F lists the events that trigger re-verification of the guide: Ph. Eur. Issues 13.1, 13.2 and 13.3, new USP–NF Issues, Pharmacopeial Forum proposals, final texts of the EU drafts and the Annex 15 draft, standards in development. When the texts change, you receive the revised guide and toolkit at no extra cost. The revision on sale is shown on this page, with the regulatory verification date.
Can I share the files with colleagues or a contract laboratory?
The licence is for individual use and internal use within the purchasing company, personal, non-exclusive and non-transferable: sharing the files with third parties, including contract laboratories, suppliers and external consultants, is prohibited. Printing is allowed for internal use only.
Before you buy: the Microbiology Laboratory and Sterility Testing hub
The 24 technical articles of the hub introduce the six themes of the guide, from the organisation of the microbiology laboratory to the qualification of a contract laboratory.
Go to the Microbiology Laboratory and Sterility Testing hub →Do you have a positive sterility test, a microbiological OOS result or a method to make defensible?
Describe the product or the test, the stage (method and suitability, routine, investigation or contract laboratory) and where you are stuck. GuideGxP will review the request and, where appropriate, may put you in touch with a specialist suited to your technical needs and your geographical area.
Describe your situation →No purchase obligation. The request is reviewed before any referral to a specialist.
GuideGxP guides do not replace official legislation or the guidance and standards cited (European Commission, EMA, PIC/S, WHO, ICH, FDA, MHRA, EDQM, USP, ISO, CEN, NSF/ANSI, PDA): they are operational support tools, do not constitute legal advice, and users remain responsible for the correct application of the rules in force in their own company context. Subscription texts are not reproduced. Numerical examples are for demonstration and are not acceptance criteria; the decision on the validity of a result and on what happens to a batch rests with the quality function. Regulatory status verified as of 04/10/2026. Torvenza Pharma S.p.A. is a fictitious company. Digital product: no physical shipping.
